This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== 1959 === January 1: Fidel Castro wins the Cuban Revolution and becomes the dictator of Cuba. In the next several years Cuban-inspired guerrilla movements spring up across Latin America. January 2: Luna 1 is launched in an attempt to impact the Moon but due to an error in device's control systems, resulted in the device missing its target by 5,990 kilometres (3,720 mi). March 3: Pioneer 4 was launched in an attempt to photograph the Moon. The probe failed to achieve its intended target of 32,000 kilometres (20,000 mi) from the Moon, reaching only 60,000 kilometres (37,000 mi), too distant for its scanners to photograph the Moon. March 10–23: The Tibetan uprising occurs. March 24: New Republic government of Iraq leaves Central Treaty Organization. May 23: The Laotian Civil War begins. July 24: During the opening of the American National Exhibition in Moscow US Vice President Richard Nixon and Soviet First Secretary Khrushchev openly debate the capacities of each Superpower. This conversation is known as the Kitchen Debate. July 31: The Basque conflict officially begins, with the aim of creating an independent state for the Basque people. August 7: Explorer 6 is launched into orbit to photograph the Earth. September: Khrushchev visits U.S. for 13 days, and is denied access to Disneyland. Instead, he visits SeaWorld (then known as Marineland of the Pacific). September 13: Luna 2 is launched and becomes the first man-made object to reach the surface on the Moon. October 4–22: Luna 3 is launched to take photographs of the far side of the Moon.
Frequently, neighborhood associations relied on restrictive covenants to mandate legal barriers to black homeownership in middle-class neighborhoods to avoid the radical disinvestment that would stem from a racially integrated neighborhood. During the legality of restrictive covenants, these deed restrictions were explicitly racist and took the form of; "people of color can't purchase this home", or only for the "Caucasian race". By leveraging the legally discriminatory capacity of restrictive covenants, neighborhood associations prioritized the stability of homeownership through the preservation of neighborhood investment and relatively high single-family home values. The homogenization of the economic and social fabric of middle-class neighborhoods reflected the white-afflicted segregation of Black Detroiters that confined these residents to Detroit's oldest and worst housing stock. However, in the midst of a mid-twentieth century movement for civil rights reform, certain hallmark legal cases of discrimination in housing such as Shelley vs Kraemer deemed restrictive covenants unconstitutional. Upon this Supreme Court ruling, neighborhood associations were forced to change their restrictive zoning regulations as black Detroiters began moving out of the dilapidated Detroit ghetto and sought residency in middle-class neighborhoods. Therefore, the repealing of restrictive covenants resulted in neighborhood associations relying on extralegal subversions of restrictive covenants to alternatively stunt black residential integration.
A eukaryotic cell can be 2 to 100 times larger in diameter than a typical prokaryotic cell. Eukaryotes can be single-celled, as in diatoms (microscopic algae), or microfungi such as yeasts, or multicellular, as in animals, plants, most fungi, and seaweed (macroalgae). Multicellular organisms are made up of many different types of cell known overall as somatic cells. Eukaryotes are distinguished by the presence of a membrane-bound nucleus that gives the eukaryote its name, which means "true nut" or "true kernel", where "nut" means the nucleus. The nucleus is the largest membrane-bound organelle in the eukaryotic cell. Other organelles present in all eukaryotic cells are the endoplasmic reticulum, ribosomes, the Golgi apparatus, mitochondria, lysosomes, peroxisomes, endosomes, and vesicles. The contents of the cell are contained within a cell membrane, and together with all the membranes of the organelles (except the mitochondria) are known as the endomembrane system. All of these membranes are involved in the secretory and endocytic pathways, modifying, packaging, and transporting proteins and lipids to and from the trans Golgi network. In mammalian cells, endocytosis includes early, late, and recycling endosomes. Some eukaryotes cells including plant cells and fungi have a cell wall. Plastids including chloroplasts feature mainly in plant cells. Most cell types include vaults. There are many cell variations among the different eukaryote groups. Many cells project one or more cellular extensions.
== United Fruit Company reefer ships == The United Fruit Company has used some type of reefers, often combined with cruise ship passenger accommodations, since about 1889. Because of their cargo was mostly bananas, they were nicknamed the "Banana Fleet". Since bananas are relatively light and the normal shipping route was to Central America and then back to various US ports, these ships were often built as combination cargo ships and what are now called cruise ships to pay for more of their operating expenses. After about 1910, they called these combination cruise and cargo ships the "Great White Fleet" based on their heat-reducing white paint. To avoid US shipping regulations and taxes they are registered in about six other countries, with very few now maintaining US registry. European associates with their own ships were often employed to ship fruit to Europe. United Brands was taken over by Chiquita Brands International in the 1980s and owns the largest fleet of banana boats in the world, but none of them now sails under the US flag. SS Pastores and SS Calamares were built in Ireland in 1912 and 1913 for the United Fruit Company as a combination cruise ship and refrigerated cargo ship. The United Fruit Company's fleet of about 85 ships was one of the largest civilian fleets in the world. These ships normally carried up to 95 cruise ship passengers and a crew to ports in Central America and then would return to the United States with passengers and a cargo of refrigerated bananas and miscellaneous cargo.
=== Human trafficking === Human trafficking is a modern form of slavery where people are forced, tricked, or pressured into working or doing sexual acts. It can happen anywhere and affect anyone, no matter their age, race, or background.
Sources: en.wikipedia.org
Reported risk factors include female sex, obesity, elevated calcium-phosphate product, medications such as warfarin, vitamin D derivatives (e.g. calcitriol, calcium-based binders, or systemic steroids), protein C or S deficiency, low blood albumin levels, and diabetes mellitus. Patients who require or have undergone any type of vascular procedures are also at increased risk for poor outcomes.
== Material advances == Recent advances in out of autoclave (OOA) processes hold promise for improving performance and lowering costs for composite structures. Using vacuum-bag-only (VBO) for atmospheric pressures, the new OOA processes promise to deliver less than 1 percent void content required for aerospace primary structures. Led by material scientists at Air Force Research Lab, the technique would save the costs of constructing and installing large structure autoclaves ($100M saved at NASA) and making small production runs of 100 aircraft economically viable.
The α-tocopheryl acetate form can replace the mineral oil in Fruend's adjuvants and is generally very efficacious in animals. The related α-tocopherol is used in AS03 in addition to squalene. Just as its makers had hoped, the AS03-based flu vaccine strong immunity despite using very little antigen; but the same vaccine also caused narcolepsy in a very small amount of people, all sharing one specific gene variant. O/W emulsions need to be stabilized so they do not revert into one large blob of oil. The more common way is by using a surfactant such as Tween-80. Another way is to use an aluminum microgel.
The trust's executive directors discussed involving the police but instead commissioned a review by the Royal College of Paediatrics and Child Health (RCPCH). Letby was taken off the unit on 30 June, and the hospital subsequently reduced cot capacity and raised the gestational‑age threshold for admissions. The RCPCH review began in September 2016. Its October report found no definitive explanation for the increased mortality rate but identified inadequate staffing and senior cover. It described concerns about Letby as subjective and unsupported by evidence. The trust's medical director asked consultant neonatologist Jane Hawdon to undertake detailed case reviews recommended by the RCPCH. Hawdon instead conducted a review of medical notes relating to 17 deaths and collapses; she was understood to have told the hospital's medical director that she had not been able to conduct the thorough review that the RCPCH had recommended due to not having had the time, and later said that she had not been "adequately briefed" about the concerns about Letby before she carried out her analysis. The report concluded that most of the deaths and collapses could be explained and might have been preventable with different care, while four warranted further local forensic review. Minutes of a subsequent board meeting recorded the medical director stating that the RCPCH and Hawdon reviews attributed the deaths to leadership and intervention issues; the board chair later said he had been misled about the depth of Hawdon's review.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.